Ruxo-allo-Studie (#631)
Laufzeit: 01.01.2017 - 31.12.2040
imported
Kurzfassung
Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: a prospective phase II trial
